SEC For	m 4 FORI	M 4		UNITE	D STA	TES	SECURITIE	ES AI		ЕХСНА		GE CO	OMMI	SSION						
						Washington, D.C. 20549											OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										Estim	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5					
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						-														
1. Name and Address of Reporting Person [*] <u>Amado Rafael</u>							er Name and Tick Lab Ltd [ZL.	Symbol	(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify										
(Last) (First) (Middle) C/O ZAI LAB LIMITED					0	3. Date of Earliest Transaction (Month/Day/Year) 12/30/2024									below) See Remarks					
314 MAIN STREET, 4TH FLOOR, SUITE 100						4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or . Line)									loint/Group Filing (Check Applicable					
(Street) CAMBRIDGE MA 02142						Form filed by One Reporting Person Form filed by More than One Reporting Person														
(City)		(State)		(Zip)																
			Tab	ole I - No	n-Deriv	ative S	Securities Ac	quired	l, Dis	sposed	of, d	or Ben	eficially	/ Owned						
Date					2. Transad Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			(A) or 3, 4 and 5)	4 and 5) Securities Beneficial Owned Fo		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount		(A) or (D)	Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)		
American Depositary Shares ⁽¹⁾ 12/30/						2024		М		21,000	(2)	Α	(3)	41,	417		D			
American Depositary Shares ⁽¹⁾ 12/31/						2024		S ⁽⁴⁾		7,583	3	D	\$26.28	1 33,	834		D			
			-				curities Acquills, warrants							Owned						
1. Title of 2. 3. Transaction Derivative Conversion Other Conversion Security (Instr. 3) Price of Derivative Derivative			Date, Ti	ransactio ode (Insti	n of	6. Date E Expiratio (Month/I	on Date		able and 7. Title and a of Securities		ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned	s i	10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownershi (Instr. 4)				

Secu (Instr	rity or Exercise		if any (Month/Day/Year)	Code ((A) or Disposed (A) or Disposed (A) or Disposed (B) or Disposed (C) (Instr. 3, 4 and 5)			(Month/Day/		of Securitie Underlying Derivative \$ (Instr. 3 and	Security	Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Restr Share Units	(3)	12/30/2024		М			21,000	(5)	(5)	American Depositary Shares ⁽¹⁾	21,000	\$0	63,000	D		

Explanation of Responses:

1. Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

2. ADSs acquired upon vesting of Restricted Share Units ("RSUs"). 3. Each RSU represents a contingent right to receive one ADS.

4. These ADSs were sold automatically to cover taxes upon vesting of RSUs.

5. These RSUs vest in equal annual installments over five years beginning on 12/30/2023, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting. Remarks:

President, Head of Global Oncology Research and Development

/s/ Bruce Blefeld,	Attorney-in-
Fact	

01/02/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.